1386458-54-3

Upstream product

• 100-46-9 benzylamine 
• 174148-03-9 (2S,4S)-4-(9H-fluoren-9-ylmethoxycarbonylamino)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 100-39-0 benzyl bromide 

Downstream Products

• 1386458-55-4 (2S,4S)-N-benzyl-4-(N'-(9-fluorenylmethoxycarbonyl)-amino)-1-pyrrolidine-2-carbamide 
• 1613552-06-9 (2S,4S )-1-((S)-2-tert-butoxycarbonylamino-2-cyclohexyl-acetyl)-4-(9H-fluoren-9-ylmethoxycarbonylamino)-pyrrolidine-2-carboxylic acid benzyl ester 
• 1613552-08-1 (2S,4S)-1-{(S)-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-2-cyclohexyl-acetyl}-4-(9H-fluoren-9-ylmethoxycarbonylamino)-pyrrolidine-2-carboxylic acid benzyl ester 
• 1613552-04-7 (2S,4S)-1-{(S)-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-2-cyclohexyl-acetyl}-4-(9H-fluoren-9-ylmethoxycarbonylamino)-pyrrolidine-2-carboxylic acid 
• 1613552-10-5 ((3S,5S )-5-benzylcarbamoyl-1-{(S)-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-2-cyclohexyl-acetyl}-pyrrolidin-3-yl)-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 1613552-09-2 {(S)-1-[(S)-2-((2S,4S)-4-amino-2-benzylcarbamoyl-pyrrolidin-1-yl)-1-cyclohexyl-2-oxo-ethylcarbamoyl]-ethyl}-methyl-carbamic acid tert-butyl ester 
• 1613552-13-8 {(S)-1-[(S)-2-((2S,4S)-4-amino-2-isopropylcarbamoyl-pyrrolidin-1-yl)-1-cyclohexyl-2-oxo-ethylcarbamoyl]-ethyl}-methyl-carbamic acid tert-butyl ester 
• 1613552-15-0 tert-butyl N-[(1S)-2-[[(1S)-2-[(2S,4S)-2-(benzylcarbamoyl)-4-[[4-[(3S)-5-[(6-bromo-2-methoxy-1-naphthyl)methyl]-3-[[(2S)-2-[tertbutoxycarbonyl(methyl)amino]propanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]benzoyl]amino]pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl] amino]-1-methyl-2-oxo-ethyl]-N-methyl-carbamate 

Relevant academic research and scientific papers

DIMERIC COMPOUNDS

Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Z, X, Q and R1 are as described in this application, and methods of using the compounds in the treatment of cancer.

SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS

The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R3, A, B, D, Q, h and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.